Unlock instant, AI-driven research and patent intelligence for your innovation.

Fully Human Antibodies Against N-Cadherin

a technology of ncadherin and human antibodies, applied in the field of human antibodies against ncadherin, can solve the problems of lack of specificity, limited psa screening, and inability to predi

Inactive Publication Date: 2014-01-16
RGT UNIV OF CALIFORNIA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PSA screening is limited by a lack of specificity and an inability to predict which patients are at risk to develop hormone refractory metastatic disease.
Recent studies advocating a lower PSA threshold for diagnosis may increase the number of prostate cancer diagnoses and further complicate the identification of patients with indolent vs. aggressive cancers (Punglia et al., N Engl J Med, 349: 335-342 (2003)).
However, neither of these two genes is secreted.
N-cadherin promotes tumor cell survival, migration and invasion, and high levels of N-cadherin expression is often associated with poor prognosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fully Human Antibodies Against N-Cadherin
  • Fully Human Antibodies Against N-Cadherin
  • Fully Human Antibodies Against N-Cadherin

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation and Characterization of Human ScFvs Specific to Human N-Cadherin

Materials and Methods

N-Cadherin Recombinant Protein Expression and Cell Lines.

[0133]Two independent N-cadherin recombinant proteins were generated (Z Wainberg); N-cadherin extracellular domains one to three (ECD1-3) and N-cadherin forth domain (ECD4). cDNA sequence was cloned using RT-PCR from mRNA preparation. Nucleic acid 160 to 497 for ECD1-3 and nucleic acid 489 to 603 were cloned into bacterial system of expression in frame with an 6 histidine tag and in vector in frame with an GST tag. Expression was induced with hours after induction the periplasmic fraction was isolated and recombinant protein purified using Ni-NTA chromatography. The protein was analyzed on SDS-PAGE for size and purity. LNCap N-cadherin transfected cells were generated. The complete N-cadherin cDNA was cloned into the vector and tranfected into LNCap by infection. PC3 cells and DU145 two Prostate cell lines were used to characterize t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 12 / 590,601, filed Nov. 9, 2009, allowed, which claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 61 / 113,042, filed Nov. 10, 2008, all of which are herein incorporated by reference in their entirety.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with Government support under contract nos. CA092131 and CA098010, awarded by the National Institutes of Health. The government has certain rights in the invention.REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK[0003]Not ApplicableBACKGROUND OF THE INVENTION[0004]Prostate cancer is the most common malignancy and the second leading cause of cancer-related death in American men. Prostate cancer is a biologically and clinically heterogeneous disease. A majority of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395G01N33/574A61K39/00
CPCA61K39/3955G01N33/574A61K2039/505C07K16/2896C07K2317/21C07K2317/622G01N33/57434G01N33/57484G01N2333/70525A61P35/00A61P35/04C07K16/18C12N15/11A61K39/395
Inventor REITER, ROBERT E.LEPIN, ERICWU, ANNA M.
Owner RGT UNIV OF CALIFORNIA